3D Printed Drugs Market Scope
These are drugs that have been developed using 3D printing technology to adapt them to individuals more safely and effectively. These medicinal products have uniform porous structures that are easily distributed in the mouth, which means that these high-dose medicinal products do not have to be swallowed intact. Therefore, this form of medication is helpful for patients with difficulty swallowing, children, the elderly, and patients who are dealing with complications such as stroke, Alzheimer's, head and neck cancer and other neurological disorders. With 3D printed drugs, it is easy to bind multiple layers of a powder mixture (API and excipients) with an aqueous liquid to get pre-measured, leak-proof unit doses that quickly disintegrate in the mouth with just a sip of liquid. With these drugs, too, patients and caregivers can experience a rapidly disintegrating, taste-masked, and convenient way to take or administer drugs, while providers can prescribe high-dose formulations for patients with swallowing problems or stressful dosing regimens.
The market study is being classified by Type (Spritam and Others), by Application (Personal Use, Hospitals, Clinics and Others) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Aprecia Pharmaceuticals (United States), GlaxoSmithKline Plc (United Kingdom), Hewlett Packard Caribe (United States) and FabRx Ltd (United Kingdom) are some of the key players profiled in the study.
AdvanceMarketAnalytics has segmented the market of Global 3D Printed Drugs market by Type, Application and Region.
On the basis of geography, the market of 3D Printed Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In the few last years, 3D printing of medical devices has gained worldwide attention; in particular, products such as cranial implants, artificial knees, and spine prostheses, which are personalized for each patient. Such products are marketed under current FDA regulations following their similarities with already existing medical devices. In 2017, the FDA released guidelines for the manufacturing of medical devices and implants; however, there are currently no regulatory guidelines on the 3D printing of other products. In 2015, the FDA released the first 3D printed drug product, Spritam® (levetiracetam). This great technological step led to an increase of research on 3D printing technology to produce drug delivery devices. However, despite the fast development in the field, there are legal and regulatory issues that need to be addressed.
- Increase In Adoption Of Personalized Drugs, And Production Of Combination Medicine
- Rise In Awareness Pertaining To The Advantages Of These Drugs
- High Demand Of Instantaneous Soluble Drugs
- Increasing Prevalence Of Dysphagia
- Growing Usage Of 3d Printing
- Growing Healthcare Infrastructure
- Increase In Healthcare Investments
- Technological Advancements In Developing Countries
- Adverse Effects Of The Drugs
- Lack Of Government Regulations
- Lack of Awareness Regarding these 3D Printed Drugs in Under Developed Regions
Key Target AudienceManufacturers of 3D Printed Drugs, Suppliers and Distributors of 3D Printed Drugs, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase